Literature DB >> 25997466

Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with ruxolitinib.

A Fabiano1, P Calzavara-Pinton2, P Monari2, E Moggio2, G Pellacani1, A M Manganoni2, G Gualdi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25997466     DOI： 10.1111/bjd.13922

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  7 in total

Review 1.  Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.

Authors:  Maria Vastarella; Gabriella Fabbrocini; Vincent Sibaud
Journal:  Drug Saf       Date:  2020-05       Impact factor: 5.606

2.  Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera.

Authors:  Marco Rastrelli; Beatrice Ferrazzi; Saveria Tropea; Alessandra Costa; Silvia Finotto; Dario Marino; Luca Campana; Paolo Del Fiore; Carlo Riccardo Rossi; Mauro Alaibac
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

3.  Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib.

Authors:  Álvaro March-Rodriguez; Beatriz Bellosillo; Alberto Álvarez-Larrán; Carles Besses; Ramon M Pujol; Agustí Toll
Journal:  Ann Dermatol       Date:  2019-02-28       Impact factor: 1.444

4.  High-risk human papillomavirus in ruxolitinib-associated sebaceous neoplasms.

Authors:  Lamiaa Hamie; Tara Bardawil; Ibrahim Khalifeh
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 May-Jun       Impact factor: 2.545

5.  Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib.

Authors:  Nader Aboul-Fettouh; Rajiv I Nijhawan
Journal:  JAAD Case Rep       Date:  2018-04-30

Review 6.  Cutaneous toxicities from targeted therapies used in oncology: Literature review of clinical presentation and management.

Authors:  Solène Huynh Dagher; Astrid Blom; Hedi Chabanol; Elisa Funck-Brentano
Journal:  Int J Womens Dermatol       Date:  2021-09-28

7.  The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypes.

Authors:  Audrey Griveau; Clotilde Wiel; Dorian V Ziegler; Martin O Bergo; David Bernard
Journal:  Aging Cell       Date:  2020-03-20       Impact factor: 9.304
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.